Aphrodyne Articles
NitroMed's super-herb in FSD
20 July 2000
ORAL IMPOTENCE DRUG IN Ph III TRIALS
28 March 1994
Showing 1-4 of 4 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
